Evidence map›Paper›PMID 30688025›Full record

ArticleCytometry. Part A : the journal of the International Society for Analytical Cytology2019

Optimization of Receptor Occupancy Assays in Mass Cytometry: Standardization Across Channels with QSC Beads.

Gerd Haga Bringeland, Lucius Bader, Nello Blaser, Lisa Budzinski, Axel R Schulz, Henrik E Mei, Kjell-Morten Myhr, Christian A Vedeler, Sonia Gavasso

Open access · hybridAbstract read
In one paragraph

Article in Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Gerd Haga BringelandDepartment of Neurology, Haukeland University Hospital, Bergen, Norway.ORCID 0000-0002-4706-6803
Lucius BaderBergen group of Epidemiology and Biomarkers in Rheumatic Disease, Department of Rheumatology, Haukeland University Hospital, Bergen, Norway.
Nello BlaserDepartment of Mathematics, University of Bergen, Bergen, Norway.
Lisa BudzinskiGerman Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany.
Axel R SchulzGerman Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany.ORCID 0000-0002-5106-0148
Henrik E MeiGerman Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany.
Kjell-Morten MyhrDepartment of Neurology, Haukeland University Hospital, Bergen, Norway.
Christian A VedelerDepartment of Neurology, Haukeland University Hospital, Bergen, Norway.
Sonia GavassoDepartment of Neurology, Haukeland University Hospital, Bergen, Norway.
Haukeland University Hospital · NOGerman Rheumatism Research Centre · DEUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Receptor occupancy, the ratio between amount of drug bound and amount of total receptor on single cells, is a biomarker for treatment response to therapeutic monoclonal antibodies. Receptor occupancy is traditionally measured by flow cytometry. However, spectral overlap in flow cytometry limits the number of markers that can be measured simultaneously. This restricts receptor occupancy assays to the analysis of major cell types, although rare cell populations are of potential therapeutic relevance. We therefore developed a receptor occupancy assay suitable for mass cytometry. Measuring more markers than currently available in flow cytometry allows simultaneous receptor occupancy assessment and high-parameter immune phenotyping in whole blood, which should yield new insights into disease activity and therapeutic effects. However, varying sensitivity across the mass cytometer detection range may lead to misinterpretation of the receptor occupancy when drug and receptor are detected in different channels. In this report, we describe a method for optimization of mass cytometry receptor occupancy measurements by using antibody-binding quantum simply cellular (QSC) beads for standardization across channels with different sensitivities. We evaluated the method in a mass cytometry-based receptor occupancy assay for natalizumab, a therapeutic antibody used in multiple sclerosis treatment that binds to α4-integrin, which is expressed on leukocyte cell surfaces. Peripheral blood leukocytes from a treated patient were stained with a panel containing metal-conjugated antibodies for detection of natalizumab and α4-integrin. QSC beads with known antibody binding capacity were stained with the same metal-conjugated antibodies and were used to standardize the signal intensity in the leukocyte sample before calculating receptor occupancy. We found that QSC bead standardization across channels corrected for sensitivity differences for detection of drug and receptor and generated more accurate results than observed without standardization. © 2019 The Authors. Cytometry Part A published by Wiley Periodicals, Inc. on behalf of International Society for Advancement of Cytometry.

Indexed as

Flow CytometryHumansIntegrin alpha4LeukocytesMultiple SclerosisNatalizumabReference StandardsSingle-Cell AnalysisIntegrin alpha4NatalizumabbiomarkersCyTOFmass cytometrymultiple sclerosisnatalizumaboptimizationQSC beadsquantitative analysisreceptor occupancystandardization

Identifiers

PMID30688025
PMCPMC6590231
OpenAlexW2911936321

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.